MRF Breakthrough Consortium Welcomes Fox Chase Cancer Center

Washington, DC, September 2, 2020 – The Melanoma Research Foundation (MRF) is pleased to announce that Fox Chase Cancer Center has been selected as the newest member of the MRF Breakthrough Consortium (MRFBC). Founded in 2010, the MRFBC is a nationwide network of 21 centers of excellence in melanoma united to accelerate research and development of the most promising melanoma treatments.

“The MRF eagerly welcomes Fox Chase Cancer Center as the newest member of its Breakthrough Consortium,” said MRF CEO Kyleigh LiPira, MBA. “Under the leadership of Dr. Jeffrey Farma, we anticipate Fox Chase to be an engaged and collaborative member site and a valued addition to this important research initiative.” The MRF has proudly supported the innovative research conducted at Fox Chase Cancer Center for many years and is confident this expanded partnership will produce even greater results and new breakthroughs for the melanoma community.

For more information about the MRFBC and additional ways the MRF supports the field of melanoma science, visit the MRF Research Center or email [email protected].